A large, international review found no convincing evidence that taking antidepressants before or during pregnancy directly causes autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in children. The analysis suggests that apparent links seen in some earlier studies are largely explained by parental mental health, genetics, and other family or environmental factors — not the medications themselves.
What the review looked at
Researchers screened nearly 2,000 papers and selected 37 higher-quality studies for pooled analysis. Those studies together covered more than 648,000 pregnancies with antidepressant exposure and almost 25 million without exposure. Outcomes assessed included ADHD, autism, intellectual disability, motor disorders, and speech or language delays. The team compared different antidepressant types, timing and dose of exposure, and even paternal antidepressant use to tease apart potential causes.
Key findings
– A small increase in diagnoses of ADHD or autism was observed in children whose parents had used antidepressants around pregnancy. That signal appeared whether antidepressant exposure occurred before or during pregnancy.
– After accounting for confounding factors — notably the pregnant person’s psychiatric history, family genetics, and sibling comparisons — the association weakened substantially or disappeared. This pattern indicates that underlying parental mental illness and shared family risks are likely driving most of the observed differences.
– Fathers’ antidepressant use during their partner’s pregnancy was also associated with higher chances of ADHD or ASD in children, supporting the idea that familial or genetic factors, not in utero drug exposure, explain much of the risk.
– No increased risk was found for intellectual disabilities, speech and language problems, or motor disorders; higher antidepressant doses did not reliably raise risk.
– Two older tricyclic antidepressants, amitriptyline and nortriptyline, showed a more consistent association with higher risk in the included studies. These drugs are less commonly used today and are typically reserved for more severe cases.
– Commonly prescribed selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline did not show clear increased risk once parental mental health was taken into account.
Limitations
The authors note limitations including differences in how studies measured exposure and outcomes, residual uncertainty from observational designs, and variability in study quality. While the pooled evidence is reassuring, it is not definitive proof of zero risk for every situation, and more research could clarify remaining questions.
Why this matters for patients and clinicians
Untreated depression and anxiety in pregnancy carry known risks for both the pregnant person and the baby — for example, higher rates of preterm birth, low birth weight, hypertensive complications, and longer-term developmental and emotional problems in children. Stopping antidepressants suddenly can also cause discontinuation symptoms (nausea, headaches, electric-shock sensations) and a relapse of depression, which in severe cases can include suicidal thoughts.
Because risks are not only about medications but also about untreated mental illness, decisions about antidepressant use during pregnancy should be individualized. Clinicians generally aim for the lowest effective dose and consider switching medications if needed, balancing the benefits of symptom control against potential medication risks.
Expert perspectives
Independent psychiatrists say the review is reassuring and echoes clinical experience: the evidence does not support a causal link between antidepressant use during pregnancy and autism or ADHD. They emphasize that fear of harming a baby has led some people to stop necessary treatment; abrupt discontinuation without medical supervision can be harmful. Managing mental health in pregnancy involves weighing competing risks and choosing the safest way to treat significant symptoms.
Bottom line
This comprehensive review supports the conclusion that antidepressant exposure before or during pregnancy is unlikely to be a direct cause of autism or ADHD in children. Observed associations in earlier studies are largely explained by parental mental health, genetics, and other family factors. Decisions about continuing, changing, or stopping antidepressant medication in pregnancy should be made with a healthcare provider, considering the severity of symptoms, past treatment response, and the risks of untreated mental illness for both parent and child.
